Recent News

• 11.04.2026 - Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
• 10.20.2026 - Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
• 10.12.2026 - Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
• 10.01.2026 - Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
• 09.22.2026 - Harmony Biosciences Recognizes World Narcolepsy Day 2026, Reflecting on Nearly a Decade of Commitment to the Sleep Community
• 09.03.2026 - Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
• 08.27.2026 - Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
• 08.06.2026 - Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
• 08.04.2026 - Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
• 07.21.2026 - Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

Recent Filings

• 11.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2026 - 8-K Current report
• 11.04.2026 - EX-99.1 EX-99.1
• 10.30.2026 - 8-K/A Current report
• 10.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.13.2026 - 8-K Current report
• 10.13.2026 - EX-99.1 EX-99.1
• 09.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.18.2026 - 144 Report of proposed sale of securities
• 09.17.2026 - 144 Report of proposed sale of securities